AI Article Synopsis

  • ACEIs and ARBs, commonly used for heart conditions, might help improve survival rates in cancer patients by affecting tumor growth; however, their impact on esophageal and gastric cancer outcomes was unclear.
  • This study analyzed 14,463 esophageal and 21,483 gastric cancer patients in Taiwan from 2008 to 2016, assessing their ACEIs/ARBs usage within six months post-diagnosis and comparing survival rates using statistical methods.
  • Results indicated that ACEIs/ARBs users had a lower risk of cancer-specific mortality, particularly in gastric cancer, suggesting these medications may provide additional benefits for cancer patients with hypertension.

Article Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are used in treating cardiovascular diseases. Previous studies indicated that ACEIs/ARBs may benefit cancer patients by inhibiting tumor angiogenesis and proliferation. The effect of ACEIs/ARBs on cancer survival in esophageal and gastric cancer is still unclear. This study is to investigate the association between ACEIs/ARBs usage and esophageal and gastric cancer prognosis.

Methods: This retrospective cohort study identified esophageal and gastric cancer patients during 2008-2016 from the Taiwan Cancer Registry, and obtained medication usage and follow-up information from the National Health Insurance Research Database and Death Registry. Analysis groups were defined as ACEIs/ARBs user or non-user based on the usage of ACEIs/ARBs within the 6 months after cancer diagnosis. The stabilized inverse probability of treatment weighting using propensity scores was applied to balance covariates between study groups. We also used Kaplan-Meier estimates and Cox regression to compare survival outcome and estimate hazard ratios (HRs).

Results: We identified 14,463 and 21,483 newly-diagnosed esophageal and gastric cancer patients during 2008-2016. ACEIs/ARBs users were associated with lower risk of cancer-specific mortality, although only significantly in gastric cancer (gastric: adjusted HR = 0.87, 95% CI = 0.78-0.97; esophageal: adjusted HR =0.88, 95% CI = 0.76-1.02). A better survival outcome was observed among patients who received higher cumulative defined daily dose of ACEIs/ARBs.

Conclusions: We found that using ACEIs/ARBs after cancer diagnosis were associated with lower risk of mortality. Our results add to the knowledge of the benefit of ACEIs/ARBs against mortality in individuals with esophageal/gastric cancer patients with hypertension.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022235PMC
http://dx.doi.org/10.1186/s12885-022-09513-4DOI Listing

Publication Analysis

Top Keywords

gastric cancer
24
esophageal gastric
20
cancer patients
20
cancer
12
angiotensin-converting enzyme
8
enzyme inhibitors
8
patients hypertension
8
aceis/arbs
8
aceis/arbs cancer
8
patients 2008-2016
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!